Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing ...

Tours, France – 10 December 2025 – Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the successful ...

OverviewThe global patient handling equipment market is anticipated to grow at a steady CAGR of around 6% over the forecast period, supported by strong demographic trends, growing safety regulations, ...

Poised for Rapid GrowthThe Global Augmented Reality (AR) and Virtual Reality (VR) in Healthcare Market is projected to grow at a remarkable CAGR of 30–35% over the next five years. This surge is ...

Unique ContentThe global medical connectors market is anticipated to grow steadily at a CAGR of approximately 7% during the forecast period, supported by the rising adoption of minimally invasive ...

Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...

Global Anatomic Pathology Market OverviewThe global anatomic pathology market is poised for a strong growth trajectory, expected to expand at a CAGR of nearly 8% during the forecast period. This ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile ...

Provepharm plans to launch two new and innovative dyes as early as 2026 - to support the rise in precision surgery and minimally invasive fluorescence-guided robotic surgery The company is refocusing ...

MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 monthsFavorable ...

New unified agency will be led by industry veteran Nicky Battle and built on proven expertise across healthcare and life sciences ·         Legacy agency leaders Jodi Amendola and Nicole ...

Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems ...